EGFR and non-small cell lung carcinoma: Notably, the efficacy of osimertinib dose escalation from 80 to 160 mg in EGFR-mutated NSCLC patients with brain metastases has been evaluated in a phase II trial, with an intracranial response rate of 54%, which demonstrated that dose escalation of osimertinib was feasible and possibly offered a therapeutic alternative for such patients [238].